Europe does not suffer consistent shortages of generic injectable drugs, although one example has been reported in the scholarly literature. Some observers assert that this stable supply is because generics are deliberately priced higher there.
Canadian policies, however, also support artificially high generic drug prices. This has not prevented crisis in the provision of generic sterile injectable drugs, which has occurred because one supplier dominates. Sandoz Canada, the country’s sole supplier of 140 injectable drugs, had to slow down production as a consequence of being accused of contamination by the U.S. FDA in November 2011. Although the FDA’s Canadian counterpart did not cite the facility, Sandoz nevertheless decided to conform to the American regulations to retain the option of exporting to the United States.